EH09-043: A Multi-Phase Study of Active Surveillance for Men with Clinical Stage T1c or T2a Localized Prostate Cancer
Aims: The purpose of this study is to identify which patients can wait for curative therapy (such as surgery, radiation or hormonal treatment) and to investigate new and better ways to identify disease progression.
Diagnosis: Stage T1c or T2a Localized Prostate Cancer
Principal Investigator: Kristian Novakovic, MD
IRB Approval Number: EH09-043
Sponsor: NorthShore University HealthSystem
Contact: Interested patients should contact study coordinator Jackie Petkewicz at 847.503.4282
Open to Enrollment: Yes

UC12-0109: A Randomized Gene Fusion Statefied Phase II Trial of Abiraterone with or without ABT-888 for Patients with Metastatic Castration Resistant Prostate Cancer
Aims: ABT-888 (Veliparib) is a drug that has been shown to inhibit the expression of enzymes that are found in tumor cells. The purpose of this study is to look at the role of a specific combination of genes known as "ETS gene fusion." Researchers will try to determine if this combinatoin of genes can predict how a patient will respond to the use of abiraterone along with prednisone, or the use of abiraterone along with prednisone plus the investigatoinal drug ABT-888. The investigators will also look at whether adding ABT-888 to abiraterone and prednisone is more effective when compared to abiraterone and prednisone without ABT-888.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH13-057
Sponsor: University of Chicago
Contact: Interested patients should contact study coordinator Kelli Shaffer at 847.570.4193 or research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

BC1-10: A Phase I/IIa Study of Safety and Efficacy of Alpharadin with Docetaxel in Patients with Bone Metastases from Castration Resistant Prostate Cancer
Aims:  This study will explore the combination of Alpharadin and docetaxel in patients with castration resistant prostate cancer and bone disease.  The objectives of this study include determining the effectiveness of Alpharadin in conjunction with docetaxel and investigating the safety of these two drugs in combination.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH12-145
Sponsor: Algeta
Contact: Interested patients should contact study coordinator Kelli Shaffer at 847.570.4193 or research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

A Phase II Study of MRI Based Functional Imaging for the Evaluation of Bone Metastasis in Men with Castrate Resistant Prostate Cancer Receiving XL184
Aims:  The primary objective of this study is to further determine the effect of XL184 (cabozantinib) on bone metastasis through the use of MRI techniques.  The investigators also seek to better understand the effect of XL184 on prostate cancer progression and bone pain.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH12-138
Sponsor: The University of Chicago
Contact: Interested patients should contact study coordinator Kelli Shaffer at 847.570.4193 or research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

UC11-0709: A Prospective Randomized Pilot Study Evaluating the Food Effect on the Pharmacokinetics and Pharmacodynamics of Abiraterone Acetate in Men with Castrate Resistant Prostate Cancer
Aims:  Abiraterone acetate is an FDA approved treatment for prostate cancer patients who have progressed after receiving prior docetaxel chemotherapy.  The current FDA labeling for abiraterone indicates that the drug be taken while fasting.  The primary objective of this trial is to compare the effect of a reduced dose of abiraterone acetate taken with food to the full, standard daily dose in the fasting state.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH12-369
Sponsor: The University of Chicago
Contact: Interested patients should contact study coordinator Kelli Shaffer at 847.570.4193 or research nurse Tara Flanagan at 847.570.1768
Open to Enrollment:
Yes

A Phase 2, Randomized, 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degaralix Alone for Patients with Prostrate Cancer with a Rising PSA or a Rising PSA or a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy
Aims:  The FDA has approved the oral drug abiraterone acetate (Zytiga ®) in combination with prednisone (a steroid) to treat patients with metastatic castration-resistant prostate cancer. Degarelix (Firmagon ®), a testosterone lowering agent given as a monthly injection, is FDA approved for the treatment of patients with advanced prostate cancer.  The purpose of this study is to evaluate abiraterone acetate and prednisone in combination with degarelix as a possible treatment for PSA recurrent prostate cancer as compared to abiraterone acetate plus prednisone alone and degarelix alone.
Diagnosis: Prostate Cancer
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH13-147
Sponsor: Memorial Sloan Kettering Cancer Center
Contact: Interested patients should contact study coordinator Kelli Shaffer at 847.570.4193 or research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

× Alternate Text